Brief: Hillstream BioPharma Licenses Technology To Develop Proprietary HER2 and HER3 Antibody Drug Conjugates Against Drug-Resistant Breast, Lung, Gastric, And Ovarian Cancers
06/07/2023 14:44
July 6 (Reuters) - Hillstream BioPharma Inc HILS.O :
* HILLSTREAM BIOPHARMA LICENSES TECHNOLOGY TO DEVELOP
PROPRIETARY
HER2 AND HER3 ANTIBODY DRUG CONJUGATES AGAINST DRUG-RESISTANT
BREAST, LUNG, GASTRIC, AND OVARIAN CANCERS
Source text for Eikon: ID:nGNX6zsg81
Further company coverage: HILS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Canton Strategic Holdings
See all newsBrief: Canton Strategic Holdings, Inc. Expected To Be Included In Russell 3000® And Russell 2000®
Brief: Canton Strategic Authorizes Share Repurchase Program For Up To $50 Million In Common Stock
Canton Strategic Holdings Q1 net loss widens on higher expenses
Brief: Canton Strategic Holdings Reports Full Year 2025 Financial And Operational Results
Brief: Canton Strategic Holdings Inc - Enters Amended Sales Agreement With Clear Street And Virtu Americas - SEC Filing